Perspective Therapeutics (CATX) vs PDS Biotechnology (PDSB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
PDS Biotechnology (PDSB) has outperformed Perspective Therapeutics (CATX) over the past year, gaining 3.0% versus a loss of 63.9%. Over five years, CATX leads with a -84.6% price change compared with -92.5% for PDSB. PDS Biotechnology is the larger company by market cap ($95.4 million vs $91.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CATX | PDSB |
|---|---|---|
| Share price | $0.7538 | $0.7774 |
| Market cap | $91.03M | $95.39M |
| 1-day change | -3.85% | -3.70% |
| YTD return | -72.59% | +0.96% |
| 1-year return | -63.93% | +2.97% |
| 5-year return | -84.62% | -92.46% |
| EPS (TTM) | $-1.25 | $-0.54 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-103.12M | $-34.50M |
| 52-week high | $6.16 | $1.79 |
| 52-week low | $0.73 | $0.195 |
| Distance from 52-week high | -87.76% | -56.57% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +1188.14% | +478.85% |
| Average volume | 2.70M | 25.64M |
| Shares outstanding | 120.76M | 122.70M |
| Employees | 163 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PDSB has outperformed CATX by 66.9 percentage points over the past year.
About Perspective Therapeutics
CATX stock →Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha.
Health Care · Biotechnology: Pharmaceutical Preparations · 163 employees
About PDS Biotechnology
PDSB stock →PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
CATX vs PDSB FAQ
Which is bigger, Perspective Therapeutics or PDS Biotechnology?
PDS Biotechnology (PDSB) is larger, with a market capitalization of $95.39M compared with $91.03M for Perspective Therapeutics (CATX).
Which stock has performed better over the past year, CATX or PDSB?
PDSB returned +2.97% over the past 12 months, compared with -63.93% for CATX (price return, excluding dividends). Past performance does not predict future results.
Are Perspective Therapeutics and PDS Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.